Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 340 in metastatic castrate-resistant prostate cancer
NCT04740034Phase 1Terminated
- Sponsor
- Amgen
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of amg 340 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events, Dose Limiting Toxicities at Day 21 and 1 more. Started Apr 2021; status: terminated.
02
Drugs
amg 340
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04740034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740034.